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cise in the size-fractionated sample.  Conclusions: Size 
fractionation of cell-free DNA may lead to the improved non-
invasive detection of fetal point mutations for   -thalassemia 
by MALDI-TOF mass spectrometry. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
  -Thalassemia, caused by   -globin gene mutations, is 
regarded as the most frequent monogenic disorder in 
man  [1] . Currently, the prenatal diagnosis of this disorder 
relies on invasive procedures, such as amniocentesis or 
chorionic villous sampling, which present a small but sig-
nificant risk for the fetus  [2] . In order to avoid this risk, 
two alternative non-invasive sources of fetal genetic ma-
terial have been explored, namely fetal cells in maternal 
blood and cell-free fetal DNA in maternal plasma  [2] . Al-
though fetal   -globin gene mutations have been correct-
ly determined using fetal cells isolated from the maternal 
circulation  [3, 4] , this approach is not suitable for the pur-
pose of clinical diagnosis due of the scarcity of fetal cells, 
requiring the use of complex enrichment and the diffi-
culty of single cell PCR procedures. On the other hand, 
the analysis of cell-free fetal DNA in maternal plasma has 
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 Abstract 
 Objectives: The selective enrichment of cell-free fetal DNA 
in maternal plasma by size fractionation leads to the im-
proved detection of paternally inherited fetal point muta-
tions when using conventional, real-time PCR, or as has more 
recently been shown by MALDI-TOF mass spectrometry. We 
have now examined the use of size fractionation in conjunc-
tion with mass spectrometry for the detection of a pater-
nally inherited codon 39 mutation of the   -globin gene. 
 Methods: Maternal plasma was obtained from an early sec-
ond trimester pregnancy at risk for   -thalassemia, where the 
father carried the codon 39 mutation and the mother was
a carrier for the IVSI-110 mutation of the   -globin gene.
Cell-free DNA was analyzed by mutation-specific PCR and 
MALDI-TOF mass spectrometry for the presence of the co-
don 39 mutation. A comparison was made between total 
cell-free DNA and that which had been enriched for a size of 
100–300 bp.  Results: The paternally inherited codon 39 mu-
tant allele was detectable in both cell-free DNA prepara-
tions, but the signal was much more pronounced and pre-
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rapidly emerged as the method of choice for non-invasive 
assessment of fetal genetic loci, especially those com-
pletely absent from the maternal genome, such as the fetal 
rhesus D gene  [5] .
 The detection of more subtle fetal genetic differences 
between mother and child, such as point mutations, is 
more difficult due to the vast preponderance of maternal 
cell-free DNA sequences in maternal plasma. For this 
reason, appropriate strategies had to be developed. In this 
context, our laboratory pioneered the approach of size 
fractionation, whereby fetal cell-free DNA fragments are 
selected for on the basis of a smaller size than maternal 
cell-free DNA fragments  [6] . We were able to detect pa-
ternally inherited point mutations of the   -globin gene 
using this procedure  [7] .
 An alternative strategy, developed by the laboratory of 
Dennis Lo in Hong Kong, was the use of MALDI-TOF 
(matrix-assisted laser desorption ionization time-of-
flight) mass spectrometry for the detection of similar fe-
tal point mutations  [8] . In our exploration of this technol-
ogy, we have observed that the enrichment of cell-free 
fetal DNA fragments by size fractionation would permit 
more precise determination of fetal SNP (single nucleo-
tide polymorphisms) loci by mass spectrometry  [9] . We 
have now set out to determine whether a similar feature 
would be observed for the analysis of   -thalassemia mu-
tations, specifically to detect paternal heritance of a co-
don 39 mutation.
 Methods and Materials 
 Subject and Sample Processing 
 Ethical approval was obtained from both participating insti-
tutions’ review boards. 12 ml plasma was shipped frozen from 
Bari, Italy, by express courier. The maternal blood sample was 
taken at week 12 + 3 prior to chorionic villous sampling. The plas-
ma was cleared by high-speed centrifugation at 16,000  g for 10 
min before the analysis. The plasma DNA was isolated and size-
fractionated according to the method used in our previous studies 
 [7] . Briefly, 10 ml of maternal plasma was used for cell-free DNA 
isolation with commercial column technology (Roche High Pure 
Template DNA Purification, Switzerland) in combination with a 
vacuum pump. The extracted cell-free DNA was separated by 1% 
agarose gel electrophoresis and the gel fraction with an approxi-
mate size of 100–300 bp was carefully excised. The cell-free DNA 
in this agarose gel fragment was extracted and eluted into 50   l 
of elution buffer using a QIAEX II Gel Extraction Kit (Qigene, 
Switzerland).
 Assay Design and PCR  
 Fetal heritance of the paternal codon 39 mutant allele was ex-
amined for using MALDI-TOF mass spectrometry combined 
with SABER (single allele base extension reaction assay) as de-
scribed previously  [8] . The assay design was kindly provided by 
Sequenom, Inc. (San Diego, Calif., USA).
 In the first step, the target gene was amplified by PCR. The 
PCR reactions consisted of 10   l of eluted size fractionated DNA, 
200 n M of each primer, 2.5 m M of Mg 2+ , 0.5 U Hotstar Taq poly-
merase (Qiagen) in a final reaction volume of 25   l. The PCR re-
action was carried out with an initial incubation at 95 ° C for 15 
min to activate the Taq polymerase, followed by 50 cycles of 94 ° C 
for 20 s, 56 ° C for 30 s and 72 ° C for 1 min. The final incubation 
was at 72 ° C for 5 min. The primers used for the PCR were:
PCR-F: 5-ACGTTGGATGATAGGCACTGACTCTCTCTG-3
PCR-R: 5-ACGTTGGATGGATCCCCAAAGGACTCAAAG-3 
 10   l of the PCR product was digested with shrimp alkaline 
phosphatase (Sequenom, Inc.) at 37  ° C for 30 min and followed by 
heating at 85 ° C for 5 min. The later step is to dephosphorylate any 
unincorporated nucleotides.
 Primer Extension and Desalting 
 The terminator mix, which contains a mixture of ddNTP and 
dNTPs, was added to the shrimp alkaline phosphatase-treated 
products. The extension reaction was carried out in an Eppendorf 
Master PCR thermal cycler (Eppendorf, Germany), using an initial 
heating step of 94 ° C for 2 min, followed by 55 cycles of 95 ° C for
5 s, 52 ° C for 5 s, and 72 ° C for 5 s. 32   l of distilled H 2 O was added 
to 18   l of extension products, followed by addition of 6 mg of 
SpectroClean resin (Sequenom, Inc.) to remove any residual salt.
 The extension primers were:
 E: 5-AGGACTCAAAGAACCTCT-3 
MALDI-TOF MS Data Acquisition and Analysis 
 Approximately 15 nl of the desalted product solution was dis-
pensed onto a 384-format SpectroChip using a MassArray  
nanodispenser (Sequenom, Inc.). The chip was analyzed by Mass-
Array  Analyzer Compact and the data was recorded and ana-
lyzed by MassArray  software.
 Results 
 The determination of absence or presence of a pater-
nally inherited mutant   -globin allele can be used to 
screen pregnancies at risk for   -thalassemia in those con-
ditions where the parents do not carry the same mutation 
 [7, 8] . In this study, the sample was taken from a pregnant 
woman carrying an IVSI-110 mutation, whereas her hus-
band carries a codon 39 mutation in the   -globin gene. 
We examined the sample in a blinded manner. Our result 
indicated that the fetus inherited the paternal codon 39 
mutant allele. This was confirmed by an independent 
analysis of fetal material obtained by chorionic villous 
sampling, performed in a routine diagnostic laboratory 
at the University of Bari, Italy. This diagnosis was also 
confirmed after delivery.
 The mass spectra showed that in the analysis of total 
cell-free DNA, the paternal mutant allele T (present as A, 
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due to the reverse extension primer) was discernable over 
the background trace ( fig. 1 a). However, the signal for 
this allele was far more pronounced when the analysis 
was performed on size-fractionated cell-free DNA 
( fig. 1 b).
 Discussion 
 Prenatal diagnosis of   -thalassemia is important in 
populations with a high prevalence of pertinent muta-
tions  [1] . An important clinical contribution will be the 
possibility to non-invasively determine which pregnan-
cies are at risk of bearing a fetus with   -thalassemia  [2] . 
This can be achieved in those cases where the parents do 
not carry the same   -globin mutation, by determining 
whether the fetus has inherited the paternal mutant allele 
or not. Although the potential usefulness of this approach 
has been investigated in previous studies  [7, 8, 10, 11] , we 
have now examined whether the combination of two 
methods, namely the enrichment of fetal cell-free DNA 
fragments by size fractionation and MALDI-TOF mass 
spectrometry, may yield improved results. Compared to 
PNA-PCR (peptide nucleic acid-PCR) the MALDI-TOF 
MS approach is much easier to handle and is robust. 
Many different mutant samples can be performed simul-
taneously in one set-up. This facet was tested on a case in 
which the father was a carrier of a codon 39   -globin mu-
tation, while the mother was a carrier for the IVSI-110 
mutation.
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 Fig. 1. Detection of paternally inherited codon 39 mutant allele in total and size-fractionated cell-free DNA by 
MALDI-TOF mass spectrometry.  a Minimal detection of the paternal mutant allele (represented by A) in the 
analysis of total cell-free DNA.  b Improved signal detection for the paternal mutant allele (represented by A) in 
the analysis of size-fractionated cell-free DNA. UEP = Unextended primer, T = wild-type allele. 
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 In our analysis we clearly observed that the use of size 
fractionation led to improved signal detection for the pa-
ternally inherited mutant allele, thereby confirming an 
observation we had previously made regarding the detec-
tion of paternally inherited SNP loci  [9] . While signal 
strength is improved, the spectrogram using size-frac-
tionated plasma DNA shows higher background peaks 
compared to total DNA. Those additional peaks most 
probably are the result of incomplete desalting of the 
sample. However, the background signals would not af-
fect the determination since they did not fall into the an-
alytical mass ranges. Although promising, our result will 
need to be verified in a much larger study, which if suc-
cessful, could pave the way for widespread clinical appli-
cation in the near future.
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